The EU Gives Mark of Approval to the Twice-Yearly HIV Prevention Injection

For expats who find it challenging to navigate healthcare in the Netherlands and also in Europe, a remarkably potent injection for HIV prevention has found its way into the market. Here’s what must be known!

In a key step for preventive medicine all over Europe, the European Commission has given marketing permission for the new drug for HIV prevention: the twice-yearly injection, lenacapavir. Marketed as Yeytuo in Europe, this injection does away with the need for a pill taken daily, which is seen as a hindrance by many when it comes to keeping up with preventive protocols.

What Received Approval?

The approval covers the other 27 members of the European Union, as well as Norway, Iceland, and Liechtenstein. The European Medicines Agency (EMA) has given the green light for its use as a Pre-Exposure Prophylaxis (PrEP). This means the medicine is intended to be used by adults and adolescents who face an increased risk of sexual HIV acquisition.

The main advantage? Longevity. An injection lasts for six months’ worth of protection and can be a great “set-it-and-forget-it” option that can boost adherence in comparison to oral pills daily.

Unprecedented Efficacy

The approval is backed by resilient clinical data, in which Gilead Sciences’ lenacapavir presented almost a 100% rate of efficacy in preventing HIV infection in trials. Such a phenomenal success rate is something that few other preventive medical interventions can claim.

“A leap forward, not a simple step,” said the representative of the European HIV analysis group. “For those living with oral PrEP daily, this injection can be life changing with few visits to the clinic- two times in a year -offering solace through robust protection.”

The Paramount Question: Access and Cost

While regulatory approval is undoubtedly first, the immediate question for expats and residents all over Europe is: when can I get it, and at what cost?

The answer is country-dependent. Now Gilead must enter into negotiations with each national health system regarding the price and reimbursement conditions. It can take a while, so the availability will be a rolling process across the continent.

Value-asceptics include reimbursement price negotiations and out-of-pocket co-pays. The U.S., where it was approved in June under the trade name Yeztugo, with a list price over $28,000 a year, hardly remains a model anymore. Already, some payers in the United States are delaying coverage so that they can choose the cheaper generic pill formulations.

European health systems are expected to negotiate lower prices, but this is only a partial solution; the cost that will trickle down to consumers will still depend considerably on the country in question, whether out of pocket or based on statutory, private insurance.

What This Means for You

1. A New Option is Coming: A highly effective, long-acting HIV prevention method will soon be available in your host country.
2. Timing is Uncertain: You are advised to keep enquiring with local health authorities or your health practitioner about any updates concerning the availability of Yeytuo in your country.
3. Check Your Coverage: If you have private international health insurance, begin inquiring about their policy on covering this new treatment once it is available locally. Understanding your plan’s formulary and approval process will be key.
4. The Pill Is the Greater Option: There are great daily and event-driven oral PrEP pills that work if taken appropriately and have always been widely available drugs, though sometimes may be reimbursed fully according to existing standards.

The Bottom Line

The European Medicines Agency approval of Gilead’s HIV ‘cure’ Yeytuo opens a new chapter in the battle against HIV as the initial phase to further choice and accessibility to those who need it most. Expatriates see this intervention as a promising new healthcare asset on the horizon; meanwhile, they must be patient because the implementation is decided upon by each European state from its own angle.

As always, the best method is to keep an open channel of communication with your doctor for the best HIV prevention strategies pertinent to your needs and circumstances.